LPCN : Summary for Lipocine Inc. - Yahoo Finance

U.S. Markets closed

Lipocine Inc. (LPCN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.01-0.17 (-4.07%)
At close: 4:00PM EDT
People also watch
MRNSSCYXTRILEVOKTNXP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4.18
Open4.21
Bid2.15 x 100
Ask9.00 x 200
Day's Range3.95 - 4.21
52 Week Range2.51 - 12.66
Volume126,794
Avg. Volume137,663
Market Cap74.57M
Beta1.89
PE Ratio (TTM)-3.86
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Lipocine to Present at 27th Annual Oppenheimer Conference

    SALT LAKE CITY, March 14, 2017-- Lipocine Inc., a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice President and CFO, will present ...

  • Zacks Small Cap Research12 days ago

    LPCN: Conserving Cash to Fund Underway DV and DF Studies

    On March 6th Lipocine Inc. (LPCN) filed its 2016 10-K in conjunction with a press release highlighting 2016 achievements.  For the year, Lipocine reported a net loss of $19 million and $1.04 per share which compares to our estimates of $20.4 million and $1.10 per share.  Lower R&D and lower SG&A both contributed to the difference.  We were under the impression that the trial costs related to the dosing validation (DV) study which began in December would cause a sequential jump in R&D expenses rather than a decline.

  • GlobeNewswire19 days ago

    Lipocine Announces Financial and Operational Results for the Full Year of 2016

    SALT LAKE CITY, March 06, 2017-- Lipocine Inc., a specialty pharmaceutical company, today announced financial and operational results for the full year ended December 31, 2016.. Initiated both a Dosing ...